Better Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Advanced preparations for potential commercial launch of BT-001 in U.S. in mid-2023

Reported positive topline results from exploratory trial for fatty liver disease

Announced restructuring and... | March 30, 2023

Related Keywords

United States ,Americans ,American ,Frank Karbe ,Drug Administration ,American Heart Association ,Company Announces Restructuring To Preserve Cash Runway ,Nasdaq ,Better Therapeutics Inc ,World Evidence Program ,American College Of Cardiology ,Exchange Commission ,Better Therapeutics ,Recent Business ,Accepted De Novo Request ,Better Therapeutic ,Additional Information ,Clinical Trial Results ,American Diabetes Association Produced ,American College ,Positive Topline Results ,Exploratory Trial ,Fatty Liver Disease ,Livvita Liver Study ,Nonalcoholic Fatty Liver Disease ,Nonalcoholic Steatohepatitis ,Magnetic Resonance Imaging ,Proton Density Fat Fraction ,Announces Restructuring To Preserve Cash Runway ,Breakthrough Device Designation ,Commercial Launch ,Full Year ,Hercules Capital ,Breakthrough Device ,Stockholder Equity ,Nc Stock Exchange ,News ,Information ,Press Release ,Dvanced ,Preparations ,Or ,Potential ,Commercial ,Launch ,F ,N ,Positive ,Topline ,Results ,Rom ,Exploratory ,Trial ,Patty ,Liver ,Estructuring Bttx Us08773t1043 ,